{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:12:53Z","timestamp":1761765173228,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.3816\/cgc.2009.n.015","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T21:04:30Z","timestamp":1250715870000},"page":"E10-E15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Efficacy of Sorafenib Therapy in Patients With Metastatic Kidney Cancer With Impaired Renal Function"],"prefix":"10.3816","volume":"7","author":[{"given":"Venkata","family":"Parsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Heilbrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aastha","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2009.n.015_bib1","first-page":"71","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CGC.2009.n.015_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(97)00506-2","article-title":"Increased incidence of serendipitously discovered renal cell carcinoma","volume":"51","author":"Jayson","year":"1998","journal-title":"Urology"},{"key":"10.3816\/CGC.2009.n.015_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00345-006-0055-5","article-title":"Long term outcomes of the surgical management of renal cell carcinoma","volume":"24","author":"Lam","year":"2006","journal-title":"World J Urol"},{"key":"10.3816\/CGC.2009.n.015_bib4","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.015_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.015_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.3816\/CGC.2009.n.015_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"10.3816\/CGC.2009.n.015_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.015_bib9","unstructured":"NCCN practice guidelines in oncology. V.1. 2008."},{"key":"10.3816\/CGC.2009.n.015_bib10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.015_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/B:UROL.0000020355.30870.3a","article-title":"Renal cell carcinoma in peritoenal dialysis patients","volume":"35","author":"Savaj","year":"2003","journal-title":"Int Urol Nephrol"},{"key":"10.3816\/CGC.2009.n.015_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1442-2042.2006.01498.x","article-title":"Renal cell carcinoma in dialysis patients: a single center experience","volume":"13","author":"Kojima","year":"2006","journal-title":"Int J Urol"},{"key":"10.3816\/CGC.2009.n.015_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1464-410X.2006.06267.x","article-title":"Renal cell carcinoma of native kidney in renal transplant recipients","volume":"98","author":"Moudouni","year":"2006","journal-title":"BJU Int"},{"key":"10.3816\/CGC.2009.n.015_bib14","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.3816\/CGC.2009.n.015_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CGC.2009.n.015_bib16","series-title":"Statistical Methods for Survival Data Analysis","first-page":"76","author":"Lee","year":"2003"},{"key":"10.3816\/CGC.2009.n.015_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.015_bib18","article-title":"Effects of renal impairment on the pharmacokinetics of sorafenib and it's metabolites","author":"Smith","year":"2007","journal-title":"Proc Am Assoc Clin Res"},{"issue":"suppl","key":"10.3816\/CGC.2009.n.015_bib19","first-page":"147s","article-title":"Pharmacokinetics (PK) and phase I study of Sorafenib(S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction: CALGB 60301","volume":"25","author":"Miller","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CGC.2009.n.015_bib20","first-page":"241s","article-title":"A phase II trial of intra-patient doseescalalted sorafenib in patients with metastatic renal cell cancer","volume":"25","author":"Amato","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.015_bib21","unstructured":"George S, Garcia JA. Dose escalation of sorafenib in metastatic renal cell carcinoma (mRCC) patients. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 360."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:09Z","timestamp":1761564009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311700222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1558767311700222"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2009.n.015","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Sorafenib Therapy in Patients With Metastatic Kidney Cancer With Impaired Renal Function","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2009.n.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}